Background/Aims: Estrogen is an important component of fetal neuroendocrine function in late-gestation fetal sheep; however, little is known about the regulation of estrogen receptor abundance in the brain and pituitary of fetuses. The present study was performed to test the hypotheses that estrogen receptor abundance in the fetal brain and pituitary are influenced by circulating estradiol concentrations and that they are acutely regulated after cerebral hypoperfusion. Methods: We studied 16 time-dated fetal sheep (124–128 days gestation) that were chronically catheterized and instrumented at least 5 days before study. Four groups (n = 4 each) were studied in which fetuses received estradiol (0.25 mg/day, producing physiological increases in fetal plasma estradiol concentrations) or placebo implants, and in which fetuses received a 10-min period of brachiocephalic occlusion (BCO) or sham-BCO. One hour after BCO or sham-BCO, fetuses were euthanized and tissues rapidly removed for analysis of estrogen receptors (ER)-α and -β at the mRNA and protein levels. Results: Both BCO and estradiol treatment were effective in changing ER expression, although the effects were region-specific. BCO dramatically increased ER-α in the pituitary and both ER-α and ER-β in the brainstem, while decreasing ER-α expression in the hypothalamus. Estradiol treatment decreased ER-α expression in the hypothalamus, whereas it increased ER-α expression in the brainstem, cerebral cortex and hippocampus. Conclusions: We conclude that the expression of ER-α and ER-β in the brain and pituitary of fetal sheep are influenced by circulating estrogen concentrations and acutely regulated in response to cerebral hypoperfusion.

Keywords:
Ischemia, Estradiol, Hypoperfusion
1.
Schaub C, Wood CE: Ontogeny of ER-alpha and ER-beta in Ovine Brain. Journal of the Society for Gynecologic Investigation. 2004;11:129A.
2.
Hatsumi T, Yamamuro Y: Downregulation of estrogen receptor gene expression by exogenous 17beta-estradiol in the mammary glands of lactating mice. Exp Biol Med (Maywood) 2006;231:311–316.
3.
Brown TJ, Scherz B, Hochberg RB, MacLusky NJ: Regulation of estrogen receptor concentrations in the rat brain: effects of sustained androgen and estrogen exposure. Neuroendocrinology 1996;63:53–60.
4.
Simerly RB, Young BJ: Regulation of estrogen receptor messenger ribonucleic acid in rat hypothalamus by sex steroid hormones. Mol Endocrinol 1991;5:424–432.
5.
Schreihofer DA, Stoler MH, Shupnik MA: Differential expression and regulation of estrogen receptors (ERs) in rat pituitary and cell lines: estrogen decreases ERalpha protein and estrogen responsiveness. Endocrinology 2000;141:2174–2184.
6.
Tong H, Wood CE: Indomethacin attenuates the cerebral blood flow response to hypotension in late-gestation fetal sheep. Am J Physiol 1999;277:R1268–R1273.
7.
Purinton SC, Wood CE: Oestrogen augments the fetal ovine hypothalamus-pituitary-adrenal axis in response to hypotension. J Physiol 2002;544:919–929.
8.
Dubal DB, Wilson ME, Wise PM: Estradiol: a protective and trophic factor in the brain. J Alzheimers Dis 1999;1:265–274.
9.
Wood CE, Giroux D: Central nervous system prostaglandin endoperoxide synthase-1 and -2 responses to oestradiol and cerebral hypoperfusion in late-gestation fetal sheep. J Physiol 2003;549:573–581.
10.
Wood CE, Giroux D: Expression of nitric oxide synthase isoforms in the ovine fetal brain: alteration by hormonal and hemodynamic stimuli. J Soc Gynecol Investig 2006;13:329–337.
11.
Wood CE, Giroux D, Gridley K: Fetal brain regional responses to cerebral hypoperfusion: modulation by estrogen. Brain Res 2003;993:84–89.
12.
Bradford MM: A refined and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem 1976;72:248–254.
13.
Byers MJ, Zangl A, Phernetton TM, Lopez G, Chen DB, Magness RR: Endothelial vasodilator production by ovine uterine and systemic arteries: ovarian steroid and pregnancy control of ERalpha and ERbeta levels. J Physiol 2005;565:85–99.
14.
Wood CE, Cousins R, Zhang D, Keller-Wood M: Ontogeny of expression of organic anion transporters 1 and 3 in ovine fetal and neonatal kidney. Exp Biol Med (Maywood) 2005;230:668–673.
15.
Al-Bader MD, Al-Sarraf HA: Housekeeping gene expression during fetal brain development in the rat-validation by semi-quantitative RT-PCR. Brain Res Dev Brain Res 2005;156:38–45.
16.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402–408.
17.
Dubal DB, Rau SW, Shughrue PJ, Zhu H, Yu J, Cashion AB, Suzuki S, Gerhold LM, Bottner MB, Dubal SB, Merchanthaler I, Kindy MS, Wise PM: Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death. Endocrinology 2006;147:3076–3084.
18.
Blurton-Jones M, Tuszynski MH: Reactive astrocytes express estrogen receptors in the injured primate brain. J Comp Neurol 2001;433:115–123.
19.
Garcia-Ovejero D, Veiga S, Garcia-Segura LM, Doncarlos LL: Glial expression of estrogen and androgen receptors after rat brain injury. J Comp Neurol 2002;450:256–271.
20.
Wise P: Estradiol exerts neuroprotective actions against ischemic brain injury: insights derived from animal models. Endocrine 2003;21:11–15.
21.
Rose’Meyer RB, Mellick AS, Garnham BG, Harrison GJ, Massa HM, Griffiths LR: The measurement of adenosine and estrogen receptor expression in rat brains following ovariectomy using quantitative PCR analysis. Brain Res Brain Res Protoc 2003;11:9–18.
22.
Blaustein JD: Estrogen receptor immunoreactivity in rat brain: rapid effects of estradiol injection. Endocrinology 1993;132:1218–1224.
23.
Parikh I, Rajendran KG, Su JL, Lopez T, Sar M: Are estrogen receptors cytoplasmic or nuclear? Some immunocytochemical and biochemical studies. J Steroid Biochem 1987;27:185–192.
24.
Shima N, Yamaguchi Y, Yuri K: Distribution of estrogen receptor beta mRNA-containing cells in ovariectomized and estrogen-treated female rat brain. Anat Sci Int 2003;78:85–97.
25.
Tschugguel W, Dietrich W, Zhegu Z, Stonek F, Kolbus A, Huber JC: Differential regulation of proteasome-dependent estrogen receptor alpha and beta turnover in cultured human uterine artery endothelial cells. J Clin Endocrinol Metab 2003;88:2281–2287.
26.
Medlock KL, Forrester TM, Sheehan DM: Short-term effects of physiological and pharmacological doses of estradiol on estrogen receptor and uterine growth. J Recept Res 1991;11:743–756.
27.
Skrzypczak M, Bieche I, Szymczak S, Tozlu S, Lewandowski S, Girault I, Radwanska K, Szczylik C, Jakowicki JA, Lidereau R, Kaczmarek L: Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium. Int J Cancer 2004;110:783–787.
28.
Nirmala PB, Thampan RV: Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. Biochem Biophys Res Commun 1995;213:24–31.
29.
Nawaz Z, Lonard DM, Dennis AP, Smith CL, O’Malley BW: Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 1999;96:1858–1862.
30.
Ceremuga TE, Yao XL, Alam HB, McCabe JT: Alterations of cullin-5 mRNA levels in the rat central nervous system following hemorrhagic shock. Neurol Res 2003;25:211–216.
31.
Wojcik C, Di NM: Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke 2004;35:1506–1518.
32.
Kenealy MR, Flouriot G, Sonntag-Buck V, Dandekar T, Brand H, Gannon F: The 3′-untranslated region of the human estrogen receptor alpha gene mediates rapid messenger ribonucleic acid turnover. Endocrinology 2000;141:2805–2813.
33.
Malter JS: Identification of an AUUUA-specific messenger RNA binding protein. Science 1989;246:664–666.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.